New combo aims to beat esophageal cancer without surgery
NCT ID NCT06869226
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 24 times
Summary
This study tests whether a combination of the immunotherapy drug camrelizumab and chemotherapy can shrink esophageal tumors enough to avoid surgery and keep the esophagus intact. About 283 adults with resectable esophageal squamous cell cancer will receive the treatment before any surgery is planned. The goal is to see if this approach can lead to long-term cancer control while preserving the organ.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.